Best health care tips on the net
 

Welcome to our health care Archive. Have fun browsing!

 

(Browse for more articles)

 

Important Issues in Pharmaceutical Industry

Many of the strongest European Biogen, a practice that became
pharmaceutical firms adopted this increasingly popular in pharmaceuticals.
strategy, seeking to develop their own The situation with Biogen and
capabilities across a relatively narrow Schering-Plough illustrates the finding
front while working with biotech of study conducted by Lerner and Merger
startups. The small, university-linked (1998), which identified 25 critical
biotechs were at first almost entirely an control rights in biotechnology
American phenomenon, and this gave the innovation alliances, in particular those
large U.S. pharmaceutical companies an regarding alliance management
initial advantage, as did the federal (manufacturing, clinical trials), the
government's support for basic research control of intellectual property,
in molecular genetics. But soon, European determination of alliance scope, equity
governments were attempting to close the in R&D companies, seats in companies'
widening biotech gap, hoping that boards.
government support would make up for the From standpoint of human resource
venture capital that was not available to management, innovation in pharmaceutical
their potential innovators. industry in the light of all accompanied
One of the interesting international trends inevitably leads to outsourcing of
hybrids was Biogen, a startup that was labor (not associated with acquisitions
built on American science and that or mergers). During 1999-2004,
quickly expanded through licensing pharmaceutical firms increased the extent
arrangements with several leading to which they outsourced R&D
pharmaceutical firms. Biogen soon had significantly. Developing economies of
operations in Germany, Switzerland, and India, China and Singapore now play
Belgium. Schering-Plough, an American active roles in the industry, creating
pharmaceutical company, collaborated with not only lower-cost sources of assistance
Biogen in the race to capture the but also potential future rivals for the
anticipated global markets for large pharmaceutical companies. From the
interferon. To enhance and protect its strategic point of view, any company's
access to Biogen's products and planning effort must answer the question
processes, Schering-Plough in the end of how this trend toward outsourcing will
bought a substantial equity position in impact the industry in future.




www.med2med.net keyword stats [2008-03-26-2008-03-26]



Other search engines trends:



Other search phrases:

schering plough health care products healthy food products
cancer research and prevention greatest health cures
healthy weight loss meal plan cancer prevention diet
control of communicable diseases manual wholesale fitness supplements
eating supplements for joint health
a healthy life senior health tips
cures for motion sickness Maine Center for Disease Control
prevention of diseases healthy solutions weight loss
mamsi life and health free health products
health nutrition product clarke health care products
healthy recipes for weight loss natural health care products
fitness supplements mental health help line
healthy weight loss menus healthy tips
omega 3 supplements self help health
healthy meal plans for weight loss american health and life
help with health frontiers in cancer prevention
health and quality of life outcomes how to cure us health care
cascade health care products institute for cancer prevention
healthy living joint health products
healthy diet supplement





1- A- B- C- 2- 3- 4- 5- 6- 7- 8- 9- 10- 11- 12- 13- 14- 15- 16- 17- 18- 19- 20- 21- 22- 23- 24- 25- 26- 27- 28- 29- 30- 31- 32- 33- 34- 35- 36- 37- 38- 39- 40- 41- 42- 43-